Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
Author:
Affiliation:
1. Receptos; a wholly owned subsidiary of Celgene Corporation; San Diego California USA
2. Bioclinica Inc; London UK
Funder
Celgene
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Reference34 articles.
1. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity;Scott;Br J Pharmacol,2016
2. Safety and efficacy of the selective sphingosine1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial;Cohen;Lancet Neurol,2016
3. Ozanimod induction and maintenance treatment for ulcerative colitis;Sandborn;N Engl J Med,2016
4. The immune modulator FTY720 targets sphingosine 1-phosphate receptors;Brinkmann;J Biol Chem,2002
5. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system;Brinkmann;Br J Pharmacol,2009
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses;Clinical Gastroenterology and Hepatology;2023-11
2. Structural determinants of sphingosine‐1‐phosphate receptor selectivity;Archiv der Pharmazie;2023-10-08
3. Ozanimod differentially preserves human cerebrovascular endothelial barrier proteins and attenuates matrix metalloproteinase-9 activity following in vitro acute ischemic injury;American Journal of Physiology-Cell Physiology;2023-10-01
4. Ozanimod Therapy in Patients With COVID-19 Requiring Oxygen Support;CHEST;2023-10
5. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis;Journal of Clinical Medicine;2023-07-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3